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Background: The number of patients using direct oral anticoagulants (DOACs) instead of vitamin K antagonists 
(VKA) is increasing and there is limited data on the safety of tooth extractions in patients taking DOACs. The aim 
of this study was to compare the amount of bleeding (AOB) and postoperative complications after tooth extrac-
tions between patients taking VKAs and patients taking DOACs without altering the anticoaguation therapy.
Material and Methods: The study consisted of four groups: Direct thrombin inhibitor group, factor Xa inhibitor 
group, warfarin group and a control group. A single tooth was extracted in each patient and routine coagulation 
test values were recorded prior to extraction. AOB was measured for 20 minutes after tooth extraction. The pa-
tients were evaluated on 2nd and 7th days after extraction for bleeding. Status of bleeding was classified as no 
bleeding, mild bleeding controlled by gauze pads, moderate bleeding controlled by hemostatic agents and severe 
bleeding required hospitalization. Analysis of variance, chi square test and correlation analysis were used for 
statistical analysis of data.
Results: A total of 84 patients (48 male, 36 female) were included in this study. The mean age of patients was 57 
(38-87) years. Mean AOB was 1388.6±913.0, 1909.29±1063.1, 3673±1415.4, 1593.33±672.5 mg for direct thrombin 
inhibitor, factor Xa inhibitor, warfarin and control groups respectively. Mean AOB was significantly higher for 
warfarin group, compared to other groups (p<0.05). The number of patients showing mild and moderate bleeding 
was significantly higher in warfarin group compared to other groups on the 2nd postextraction day (p=0.001). 
No bleeding was occurred in control group on 2nd and 7th postextraction days and no bleeding was occurred in 
direct thrombin inhibitor group on 7th postextraction day. The number of bleeding events among groups was not 
statistically significant on 7th postextraction day (p=0.251). 
Conclusions: Patients taking warfarin had more bleeding compared to patients taking direct oral anticoagulants 
after tooth extractions. In patients taking direct oral anticoagulants simple tooth extractions can be safely carried 
out without altering the anticaogulant regimen with the use of local hemostatic agents.
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Introduction
Treatment or prophylaxis of thromboembolism in sever-
al diseases and medical conditions including prosthetic 
cardiac valves, chronic atrial fibrillation, stroke, recur-
rent myocardial infarction, deep vein thrombosis and 
pulmonary embolism may require extended anticoagu-
lation therapy. For more than 50 years VKAs have been 
the only oral anticoagulant drugs available (1). Warfarin 
is a coumarin derived drug that shows its anticoagulant 
effect by reduced synthesis of Vitamin K dependent 
factors II, VII, IX, X, proteins C and S. Warfarin is the 
most commonly prescribed VKA however it has many 
disadvantages like food and drug interactions, the need 
for individual dosing, regular monitoring and dose ad-
justment, slow onset and offset of action and a hyperco-
agulable state as a result of warfarin-mediated protein 
C and S deficiency that develops in some patients (2,3). 
To overcome these disadvantages and difficulties new 
oral anticoagulants or DOACs have been developed in 
the recent years (4). Unlike warfarin, DOACs act by in-
hibiting a specific targeted step in the coagulation cas-
cade. The majority of DOACs including rivaroxaban(5) 
and apixaban (6) inhibit FXa. Dabigatran etexilate is the 
only available oral direct thrombin inhibitor for clinical 
use (7). The use of DOACs for thromboembolic disease 
treatment in place of VKAs has increased over the past 
years. The management of patients taking VKAs who 
require tooth extractions/oral surgery is well document-
ed in the literature (8-14). However, there are only limit-
ed amount of clinical studies in patients taking DOACs 
who require dental extractions/oral surgery (15-18). 
The aim of this prospective, observational study was to 
compare the AOB and postoperative complications af-
ter tooth extractions in patients taking warfarin, direct 
thrombin inhibitors and factor Xa inhibitors. 
Material and Methods
Sixty-two patients taking oral anticoagulants and 24 
healthy patients taking no anticoagulant were enrolled 
in this study. A medical history was taken, clinical and 
radiographic examinations were performed at first visit. 
Çukurova University Local Ethics Committee approved 
the study protocol and the guidelines established in the 
Declaration of Helsinki were followed during the study. 
The patients who participated in the study signed an in-
formed consent. 
The inclusion criterion was having a tooth indicated 
for extraction. Exclusion criteria were: local infection, 
inflammation or pathology associated with the tooth; 
conditions that may complicate the extraction includ-
ing extensive caries, large restorations, roots that have 
severe dilaceration, ankylosis and hypercementosis; 
hematologic diseases; thrombocytopenia; hepatic/renal 
dysfunction; using an anti-platelet drug; INR>4 in pa-
tients taking warfarin.
The study was consisted of three anticoagulant groups 
and a control group; Patients taking direct thrombin in-
hibitor, patients taking factor Xa inhibitor, patients tak-
ing warfarin, patients taking no anticoagulants (control 
group). All patients in direct thrombin inhibitor group 
were taking dabigatran etexilate 150mg/12h (Pradaxa®, 
Boehringer Ingelheim Pharma GmbH & Co. KG). Three 
patients in FXa inhibitor group were taking apixaban 
5mg/12h (Eliquis®, Bristol-Myers Squibb Co. & Pfiz-
er) and 18 patients were taking rivaroxaban 20mg/24h 
(Xarelto®, Bayer Schering Pharma AG). The warfarin 
(Coumadin®, Zentiva, Istanbul) dosage was adjusted 
for a target INR value of 2.0 to 3.0 depending on the 
patient’s INR levels.
Blood samples were taken from all patients for BUN, 
creatinine, AST, ALT, prothrombin time (PT), INR and 
platelet count measurements on the day of extraction. 
Thrombin Time (TT) and anti-FXa measurements were 
performed for patients in direct thrombin inhibitor and 
factor Xa inhibitor groups respectively. When neces-
sary, 2gr. amoxicilin were given to the patients for bac-
terial endocarditis prophylaxis 30-60 minutes before 
the extraction. A single tooth was extracted from each 
patient without stopping anticoagulants. 
Extractions were performed under local anesthesia 
without epinefrine (3% Mepivacaine, Safecaine®, Vem 
Ilac, Istanbul, Turkey). Prior to extraction, the oral cav-
ity was isolated from salivary secretions by specific 
saliva blocking barriers (Neodrys®, Henry Schein, 
Germany) placed on orifices of parotid glands, gauze 
pads placed on the submandibular gland ducts and by 
continuous suctioning with a surgical aspirator. All ex-
tractions were performed in an atraumatic fashion us-
ing elevators and forceps by the same surgeon who was 
blinded to the type of patient’s anticoagulant therapy. 
The method previously described by Karsli et al. was 
used to measure the AOB (10). At completion of the ex-
traction, gauze pads were used to control bleeding from 
the extraction sockets, and these were subsequently 
changed for 20 minutes. Each gauze pad was placed 
over the extraction socket and changed with a new 
pad once it absorbed a sufficient amount of blood. The 
weights of gauze pads used before and after tamponade 
were measured using a fine electronic weight measure-
ment device (Shimadzu, Kyoto, Japan). Weight differ-
ences before and after tamponades were interpreted as 
the AOB (in miligrams). After 20 minutes, each extrac-
tion socket was packed with oxidized cellulose dressing 
(Surgicel; Ethicon, Neuchatel, Switzerland) and sutured 
with 3.0 silk sutures (Dogsan, Istanbul, Turkey). Par-
acetamol 500 mg three times a day was prescribed for 
pain control. Patients were given additional gauze pads 
to be used if bleeding continued and instructed to call 
the surgeon or visit the oral and maxillofacial surgery 
department in case of severe bleeding. Patients were 
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seen again on 2nd and 7th days after extraction for suture 
removal and evaluation of any postextraction bleeding. 
Status of postextraction bleeding was classified as no 
bleeding, mild bleeding controlled by gauze pads, mod-
erate bleeding controlled by hemostatic agents and se-
vere bleeding required hospitalization.
- Statistical analysis
All analyses were performed using SPSS 20.0 statisti-
cal software (SPSS, IBM, Chicago, IL). Categorical 
variables were expressed as numbers and percentages, 
whereas continuous variables were summarized as 
mean and standard deviation where appropriate. Chi-
square test was used to compare categorical variables 
between the groups. For normal distributed data, One-
Way ANOVA test was used to compare more than two 
groups. Bonferroni test was used for multiple compari-
sons of groups. Pearson’s correlation was used to assess 
the correlation between the AOB and TT in thrombin 
inhibitor group and between the AOB and Anti-FXa 
value in factor Xa inhibitor group. The statistical level 
of significance for all tests was considered to be 0.05. 
Results
Two patients taking direct thrombin inhibitor were ex-
cluded from the study because of elevated ALT-AST 
levels. A total of 84 patients (48 male, 36 female) were 
included in this study. The mean age of patients was 57 
(38-87) years. Demographic data of the patients, type of 
extracted tooth and indication for anticoagulant therapy 
were summarized in Table 1. There was no statistically 
significant difference among groups, in terms of age 
and type of extracted tooth (p>0.05). No patients re-
quired flap elevation, root separation or bone removal. 
No intraoperative complications or severe intraopera-
tive bleeding occurred in any patient. The mean AOB 
after tooth extraction and bleeding status on 2nd and 7th 
postextraction days according to groups were summa-
rized in Table 2. The mean AOB in warfarin group was 
significantly higher than the other groups (p<0.05). The 
difference between thrombin inhibitor, factor Xa inhib-
itor and control groups was not statistically significant 
in terms of AOB (p1-2=0.798, p1-4=1.00, p2-4=1.00) (Fig. 










































Indication for anticoagulant therapy
Prosthetic Cardiac Valve, n (%)
Atrial Fibrillation, n (%)
Thromboembolism(PE/DVT), n (%)
Myocard Infarctus, n (%)
Cerebrovascular Accident, n (%)











































Table 1. Patient characteristics, indications for anticoagulant therapy and type of extracted tooth
* Pearson Chi-square test was used for this result.
** OneWay ANOVA test was used for this result.
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7th postextraction days. No severe bleeding requiring 
hospitalization was encountered following the extrac-
tions. The number of patients showing mild and moder-
ate bleeding was significantly higher in warfarin group 
compared to other groups on the 2nd postextraction day 
(p=0.001). No bleeding occurred on 7th postextraction 
day for thrombin inhibitor and control groups. One pa-
tient in factor Xa inhibitor group (4.8%) and 1 patient 
in warfarin group (4.5%) had mild bleeding, and 2 pa-
tients in warfarin group (9.1%) had moderate bleeding 
on 7th day. However these results were not statistically 
significant (p=0.251). Table 3 shows the distribution of 
the laboratory results of the patients according to the 
groups. The mean INR and PT measurements were sta-
tistically significant between the groups (p<0.05). The 
direct thrombin inhibitor group and the control group 
were found to have similar INR and PT values. How-













1388.6±913.0 1909.2±1063.1 3673.0±1415.4 1593.3±672.5 p<0.05*












































* OneWay ANOVA test was used for this result.
** Pearson Chi-square test was used for this result.
Table 2. Amount of bleeding (AOB), bleeding on 2nd and 7th days after tooth extraction
Fig. 1. Graphic shows the AOB (mg) among groups.
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tor Xa and warfarin groups compared to direct throm-
bin inhibitor group and control group. On the other 
hand, no statistically significant difference was found 
between factor Xa and warfarin group (p=0.099). The 
mean platelet counts was not statistically significant 
among the groups (p=0.089). The mean TT in throm-
bin inhibitor group was 106.0±29.8 seconds, which was 
higher than normal range of TT (14-21 seconds). The 
mean anti-FXa was 2.98±9.2 UI/ml in factor Xa inhibi-
tor group was also higher than the normal range (0-0.1 
UI/ml). However no statistically significant correlation 
was found between the AOB and TT in thrombin inhibi-
tor group (r=0.04; p=0.870), and the AOB and Anti-FXa 
value in factor Xa inhibitor group (r=-0.10; p=0.657).
Discussion
Discontinuation of oral anticoagulants may lead to se-
vere thromboembolic complications, and in case of mi-
nor surgery these medications should not be stopped if 
feasible. There is a considerable amount of literature 
that supports the continuation of VKAs in minor surgi-
cal procedures such as tooth extraction. Recent studies 
have shown that in patients taking warfarin, tooth ex-
tractions can be carried out safely with the aid of local 
hemostatic measures if the INR is less than 4 (11,14,19). 
Predictable pharmacokinetics, rapid onset of action, 
lower risk of food-drug interaction and a short half-life 
are advantages of DOACs compared to VKAs. Unlike 
VKAs, DOACs do not require regular monitoring or 
dose titration. Thus, management of patients taking 
these medications during tooth extraction may be safer 
and easier (3,20). However, a high level of scientific 
evidence for direct oral anticoagulant use during tooth 
extractions is limited. In a review by Muñoz-Corcuera 
et al. the authors suggest that each case should be treat-
ed individually in accordance to the risk of embolism, 
postoperative bleeding and renal function (21). Depend-
ing on the risk of bleeding Curto et al. classified dental 
treatments in two groups: procedures with a low risk of 
bleeding and procedures with medium to high risks of 
bleeding (22). Low-risk procedures include simple tooth 
extractions, oral surgery lasting less than 45 minutes 
and mucogingival surgical procedures. The extraction 
of more than three teeth at once and oral surgery last-
ing more than 45 minutes were considered medium-
high risk procedures. In this group, the instructions to 
stop DOACs should be consulted with the specialist 
physician. The authors suggest that for low risk pro-
cedures discontinuation of dabigatran is not necessary 
and apixaban can be administered at a usual dose on 
the day, after the procedure (23). For medium and high 
risk procedures apixaban and dabigatran should be sus-
pended for at least 24h and 48h respectively. Also the 
time of suspension should be extended for patients with 
altered renal function. If the drug suspension period is 
prolonged bridging therapy with low molecular weight 
heparin should be considered. Beyer-Westendorf et al. 
took data from a larger ongoing study of 2179 patients 
to evaluate the peri-procedural safety and management 
of DOACs(24). The majority of patients in the study 
were taking rivaroxaban (76%), followed by dabigatran 
(23.5%) and apixaban (0.5%). The authors defined three 
categories of procedures as minimal, minor and major 
according to the severity of tissue trauma and the risk 
of bleeding. In minor procedures category that included 
tooth extractions, the authors identified 3 (0.5%) ma-
jor bleeding, 20 (3.1%) non-major clinically relevant 
bleeding and 6 (0.9%) minor bleeding. The prevalence 
of bleeding was found to be higher in the group of pa-
tients who had received heparin bridging, compared to 
patients continued DOACs or patients interrupted an-
ticoagulants. In conclusion of the study heparin bridg-
ing was not recommended. In the present study, tooth 
extraction was performed without interruption of DO-
ACs and no major bleeding was observed in any patient. 
Morimoto et al. extracted twenty-three teeth including 
two surgical extractions in 19 patients while continuing 
DOACs (17). The teeth were extracted in a minimally 
invasive fashion and the authors used local hemostatic 
measures after extraction. Three patients taking apixa-
ban, and two patients taking rivaroxaban showed mild 
bleeding however one patient taking rivaroxaban who 
Thrombin Inhibitor FXa inhibitor Warfarin Control p
PT (sec)
Mean ± SD 12.8±1.4 20.4±13.7 24.8±8.9 11.5±0.8 p<0.05
INR
Mean ± SD 1.11±0.1 1.81±1.3 2.33±0.5 1.00±0.1 p<0.05
Platelet 
Mean ± SD 243.2±51.8 x 10
3 220.0±76.8 x 103 241.7±53.1 x 103 269.4±68.3 x 103 0.089
Table 3. PT, INR and platelet count in groups
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had a surgical extraction showed persistent post-opera-
tive bleeding on 2nd postextraction day. This patient had 
mild oozing from the surgical site even after local in-
tervention using electrocautery and oxidized cellulose 
until the 7th day. No postoperative bleeding event was 
observed in other patients. Breik et al. reported a case 
series of 5 patients taking dabigatran who underwent 
tooth extraction (25). In one patient dabigatran was 
stopped 48 hours prior to extractions, in 3 patients a 
single tooth was extracted without drug interruption 
and there was no adverse bleeding in these 4 patients. 
However in one patient 18 teeth were extracted with 
drainage of a facial abscess under general anesthesia 
without drug interruption, which resulted in a signifi-
cant bleeding. The patient needed to return to operating 
room and dabigatran was stopped to control the bleed-
ing. Hanken et al. compared the postoperative bleeding 
events after 52 oral procedures including bone removal 
for tooth extraction and implant placement, performed 
while taking factor Xa inhibitor (rivaroxaban) with 
285 oral procedures performed in patients taking no 
anticoagulant (18). The authors described postopera-
tive bleeding event as a condition requiring additional 
treatment, which may correspond to moderate bleeding 
in our study. In this study 11.5% bleeding events inci-
dence was reported for rivaroxaban, which was similar 
to our results for moderate bleeding (9.5%). The authors 
concluded that, although it is managable, continuing 
anticoagulation therapy with rivaroxaban significantly 
increases the risk of postoperative bleeding after oral 
surgery. Slightly increased incidence of bleeding events 
seen in this study may be explained by the bone removal 
for tooth extraction in the majority of the cases (97%). 
Mauprivez et al. compared the number of bleeding 
events after tooth extraction in 31 patients taking DO-
ACs and 20 patients taking VKAs with an INR between 
2.0 and 3.0 without interrupting their medications (15). 
The authors defined a bleeding event as persistent ooz-
ing or marked hemorrhage despite mechanical com-
pression with gauze pads for 20 minutes. Five patients 
taking DOACs had seven bleeding events, and four pa-
tients taking VKAs had five bleeding events during the 
postoperative follow-up period. The difference between 
two groups was not statistically significant in terms of 
number of bleeding events. Eleven (91.67%) bleeding 
events were mild and controlled by gauze pads, and one 
(8.33%) was managed with a revision of the wound, ap-
plication of fibrin glue, and resuturing. Similar to our 
study, the authors reported no bleeding that required 
hospitalization or blood transfusion. In contrast to our 
study no bleeding events were occurred after the first 
3 postoperative days. Total bleeding events reported in 
this study (22.58%) was slightly higher than our results 
for thrombin inhibitor group and FXa inhibitor groups 
combined (18.42%). Two (9.52%) bleeding events were 
observed in 21 simple tooth extractions for patients tak-
ing dabigatran, which was similar to our study (11.8%). 
Eight (%29.63) bleeding events were observed in 27 
simple extractions for patients taking Factor Xa inhibi-
tor, which was slightly increased, compared to our re-
sults (23.8%). 
In the present study the mean INR value was signifi-
cantly higher in factor Xa inhibitor and warfarin groups 
compared to other groups. In patients taking warfarin, 
INR>2 is the therapeutic goal of anticoagulant therapy. 
Additionally, in patients taking factor Xa inhibitor an 
increase can be observed in INR. However, in patients 
using FXa inhibitor, there is no need for regular INR 
monitoring and a fixed dose is preferred. TT measured 
in the direct thrombin inhibitor group and anti-FXa 
measured in the FXa inhibitor group was higher than 
the normal ranges. However, no correlation could be 
found between these blood tests and AOB. Therefore, 
these tests are questionable for clinical practice. 
The comparison of bleeding both quantitatively and in 
terms of postextraction bleeding events, the fixed dos-
age of DOACs and the prospective design were the main 
strengths of this study. It wasn’t possible to extract the 
same type of tooth from all patients and this could be 
considered as a weakness of this study. However the dis-
trubution of types of tooth among the groups wasn’t dif-
ferent statistically. Perhaps a more important weakness 
of this study is that the time period between drug intake 
and tooth extraction was not recorded, which could be 
an important issue when considering the short half-life 
of these drugs. The most important limitation of this 
study was only a single uncomplicated tooth extraction 
was carried out for each patient. Multiple extractions 
or more invasive oral surgical procedures may show a 
different outcome and should be evaluated with further 
studies. Another limitation of this study was only 3 pa-
tients using apixaban was included in the study. 
In conclusion, for simple tooth extractions DOACs are 
safe drugs in terms of bleeding and extractions can be 
carried out without interrupting or altering anticoagu-
lant regimen with the aid of local hemostatic measures. 
Further studies are needed to evaluate the necessity of 
alteration in drug regimen for patients taking DOACs 
who underwent oral surgical procedures. 
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